A groundbreaking investigation conducted by researchers at the University of Virginia (UVA) Health System, specifically from the Beirne B. Carter Center for Immunology Research and the UVA Comprehensive Cancer Center, has unveiled a significant and potentially concerning association between severe bouts of respiratory viral infections, such as COVID-19 and influenza, and an increased likelihood of developing lung cancer years after recovery. The study, which meticulously examined the biological mechanisms and clinical implications, also highlights a critical protective role for vaccination in mitigating these detrimental long-term effects.
The research team, spearheaded by Dr. Jie Sun, a distinguished scientist at the UVA School of Medicine, has illuminated how profound respiratory infections can fundamentally alter the cellular landscape and immune response within the lungs, creating an environment conducive to the inception and accelerated progression of cancerous tumors. This intricate interplay, which can persist for months or even years post-infection, has led to a crucial recommendation for medical professionals to maintain heightened vigilance and implement proactive monitoring strategies for individuals who have endured severe episodes of COVID-19, influenza, or pneumonia, thereby facilitating the early detection of lung cancer when therapeutic interventions offer the greatest chance of success.
"The lingering inflammatory state that can afflict the lungs following a significant encounter with COVID-19 or influenza presents a fertile ground for the subsequent development of cancer," explained Dr. Sun, who also holds co-director positions at UVA’s Carter Center and is a member of the Division of Infectious Diseases and International Health. "The optimistic aspect of our findings is that widespread vaccination appears to effectively preempt many of these harmful cellular modifications that otherwise pave the way for lung tumorigenesis."
Respiratory pathogens, including the viruses responsible for influenza and COVID-19, are widely recognized as primary instigators of lung damage. However, the precise mechanisms by which this acute injury might translate into an elevated risk of lung cancer over extended periods have remained largely elusive until now. To bridge this knowledge gap, Dr. Sun and his dedicated team embarked on a comprehensive research endeavor, utilizing both meticulously controlled laboratory experiments involving mice and extensive analysis of human patient data.
The results derived from these investigations were both compelling and deeply informative. Laboratory mice that experienced severe lung infections exhibited a demonstrably higher incidence of lung cancer development in subsequent stages and consequently faced a poorer prognosis from the disease. This observation was mirrored in the retrospective analysis of human health records, where individuals who had required hospitalization due to COVID-19 demonstrated a statistically significant increase in the rate at which they were diagnosed with lung cancer.
The statistical evaluation of patient data revealed a 1.24-fold increase in the occurrence of lung cancer among individuals who had been admitted to the hospital for COVID-19 treatment. This elevated risk factor was found to be independent of other well-established risk modifiers, such as an individual’s smoking history or the presence of co-existing medical conditions, commonly referred to as comorbidities.
"These findings carry immediate and profound implications for how we approach patient care and surveillance in the aftermath of severe respiratory viral infections," stated Dr. Jeffrey Sturek, an accomplished physician-scientist at UVA and a key collaborator on this study. "For a considerable time, we have understood that factors like smoking substantially augment the predisposition to lung cancer. The outcomes of this current research suggest that we may need to re-evaluate severe respiratory viral infections with a similar level of concern. For instance, in certain patient populations identified as being at high risk for lung cancer due to their smoking habits, we routinely recommend close monitoring through scheduled low-dose computed tomography (CT) scans of the lungs to enable early detection. It is plausible that future research protocols will advocate for comparable screening strategies following severe respiratory viral infections."
Delving deeper into the underlying biological processes, the experimental investigations conducted with mice provided crucial insights into the mechanisms by which severe infections might predispose individuals to lung cancer. The research team meticulously documented substantial alterations within specific types of immune cells, namely neutrophils and macrophages, which ordinarily play a vital role in defending the pulmonary system.
Following the onset of severe infection, a subset of neutrophils began to exhibit aberrant functional behavior, contributing to a persistent inflammatory milieu characterized as "pro-tumorigenic." This designation signifies an environment that actively fosters and supports the growth of cancerous cells. Concurrently, the scientists observed significant functional and structural modifications in epithelial cells, the cells that form the inner lining of the lungs and the delicate air sacs crucial for respiration.
The study also yielded exceptionally encouraging findings concerning preventative measures. Evidence suggested that prior vaccination effectively thwarted many of the cellular and molecular changes in the lungs that are intrinsically linked to cancer development. Vaccines function by priming the immune system to mount a more robust and efficient response to viral incursions, thereby diminishing the overall severity of the illness.
Intriguingly, the researchers noted that the heightened risk of lung cancer was predominantly observed in individuals who had experienced severe COVID-19. Conversely, those who had contracted milder forms of the infection did not exhibit this elevated risk; in fact, some even showed a slight decrease in lung cancer incidence, underscoring the critical role of infection severity.
Despite these promising insights into prevention, the researchers issue a cautionary note, emphasizing that a considerable number of individuals who have survived severe COVID-19 or other serious respiratory infections may indeed face an elevated risk of developing lung cancer in the future.
"Considering that tens of millions of people globally have experienced protracted pulmonary sequelae following COVID-19 infection, these findings carry substantial weight for clinical practice," the researchers articulated in their peer-reviewed scientific publication. "Individuals recuperating from severe viral pneumonia, particularly those with a history of smoking, might derive significant benefit from enhanced lung cancer surveillance protocols. Furthermore, the prevention of severe infection through robust vaccination programs could potentially confer indirect protective advantages against cancer development."
The implications of this research extend directly to the critical domains of early detection and timely treatment of lung cancer. Dr. Sun and his colleagues aspire for their work to empower clinicians with improved tools to identify patients who may be at a heightened risk of developing lung cancer following severe respiratory infections. Earlier identification holds the promise of initiating therapeutic interventions sooner, thereby substantially improving patient prognoses and outcomes.
Moreover, the research team believes that their findings can serve as a foundational element in the development of novel strategies aimed at preventing or effectively treating lung cancer that arises in the context of prior lung infections.
"Our overarching objective is to equip healthcare providers with the ability to accurately identify individuals who may face an increased susceptibility to lung cancer subsequent to a severe infection, and to devise targeted interventions for both the prevention and treatment of lung cancer in these specific patient cohorts," Dr. Sun stated. "We also hold the conviction that the benefits of vaccines extend beyond merely averting acute hospitalization following viral exposure. They may also play a crucial role in mitigating the long-term consequences of severe infection, including the type of immunological scarring that can ultimately elevate cancer risk."
The pursuit of enhanced understanding and more effective treatments for complex diseases remains a central tenet of UVA’s Paul and Diane Manning Institute of Biotechnology. This institute is dedicated to accelerating innovative research endeavors, such as the seminal work undertaken by Dr. Sun’s team, and to streamlining the translation of fundamental laboratory discoveries into tangible new therapeutic modalities.
The Beirne B. Carter Center for Immunology Research (CIC) at UVA was established through the generous support of Beirne B. Carter, and the Beirne Carter Foundation continues to be a vital patron of its research initiatives. Scientists at the CIC are actively engaged in studying a broad spectrum of diseases, including infections, various forms of cancer, cardiovascular ailments, chronic pulmonary conditions, the intricate microbiome, and autoimmune disorders, with the ultimate aim of developing groundbreaking therapies and cures.
The UVA Comprehensive Cancer Center stands as a testament to excellence, recognized as one of only 57 cancer centers in the United States to receive the prestigious "comprehensive" designation from the National Cancer Institute. This distinction signifies exceptional standards in patient care and advanced cancer research.
The findings from this pivotal study have been formally published in the esteemed scientific journal Cell. The research team involved in this extensive project includes Wei Qian, Xiaoqin Wei, Andrew J. Barros, Xiangyu Ye, Haibo Zhang, Qing Yu, Samuel P. Young, Eric V Yeatts, Yury Park, Chaofan Li, Sijie Hao, Gislane Almeida-Santos, Jinyi Tang, Harish Narasimhan, Nicole A Kirk, Valeria Molinary, Ying Li, Li Li, Bimal N. Desai, Peter Chen, Kwon-Sik Park, Anny Xiaobo, Jeffrey M. Sturek, Wei Chen, In Su Cheon, and Jie Sun.
Financial support for this critical research was generously provided by the National Institutes of Health through grants AI147394, AG069264, AI112844, HL170961, AI176171, AG090337, R01HL179312, F31HL170746, T32AI007496, T32CA009109, R01AI155808, and R01HL162783; a UVA Comprehensive Cancer Center Collaborative Grant, U01CA224293; a UVA Pinn Scholar Award; a UVA Shannon Fellowship; a UVA Comprehensive Cancer Center Lung TRT Pilot Grant; an American Lung Association Catalyst Grant, T32GM139787-01; and a UVA Parsons-Weber-Parsons Fellowship.
About the Author
